Active Clinical Trials for Prostate Cancer

This page lists many active clinical trials (protocols) at Fox Chase Cancer Center for Prostate cancer. In addition to the title, some studies below have brief summaries.

Clinical trials, or protocols, are research studies conducted with people who volunteer to take part. You benefit by having access to new cancer treatments and options not otherwise available, in addition to the excellent care offered at Fox Chase.

For more information on clinical trials at Fox Chase Cancer Center, or to find a study, call 1-888 FOX CHASE (1-888-369-2427).
Open DateTrial NumberPrincipal InvestigatorTitle
09/18/2003IRB03835/03-835Eric Horwitz Prospective Collection Of Characteristics And Outcome Of Patients Treated For Prostate Cancer At Fox Chase Cancer Center
08/20/1996IRB96091/96-091Elias Obeid Prostate Cancer Risk Assessment Program
10/28/201515-7002/15-7002Lori Goldstein Molecular Analysis for Therapy Choice (MATCH)
01/01/201815-8013/15-8013Suzanne Miller Improving Decision-Making for Low Health Literate Prostate Cancer Patients
01/13/201716-1043/16-1043Alexander Kutikov Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination thru Engagement in Mindfulness Education
11/02/202020-1040/20-1040Matthew Zibelman A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer
07/30/202120-9040/20-9040Andres Correa Assessing the Safety and Efficacy of Extended VTE Prophylaxis in Patients Undergoing Radical Prostatectomy
07/15/202120-1057/20-1057Efrat Dotan A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
07/01/202120-1072/20-1072Anthony Olszanski A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) In Combination with Cemiplimab In Patients with Advanced Solid Tumors
06/10/202121-2006/21-2006Mark Hallman Phase III Study of Local or Systemic Therapy INtensification DIrected in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
11/13/202017-8003/17-8003Elias Obeid Exploring the Prostate Cancer Genome in Men of African Descent
08/23/201717-1022/17-1022Anthony Olszanski A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers
05/01/201817-8009/17-8009Camille Ragin Cancer Genome Registry to Promote Health Equity Among Patients of African Ancestry
11/13/201717-9042/17-9042Jeffrey Farma Impact of Enhanced Recovery After Surgery on Perioperative Outcomes Following Elective Complex Cancer Surgery
04/28/202118-8004/18-8004Alexander Kutikov Prospective Data Collection for Analysis Comparing Detection of Clinically Significant Prostate Cancer Using Us/Mri Fusion Targeted Biopsy With the Traditional Standard 12-core Template Biopsy
02/25/201918-8012/18-8012Alvaro Pereira-Rico GU-149 Observing Adherence to Oral Anticancer Therapies in Advanced Prostate and Breast Cancer Patients Treated at an Urban Hospital
08/12/201919-2008/19-2008Jeffrey Farma Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer
07/10/201919-4001/19-4001Sanjeevani Arora Screen for Constitutional Genomic Instability and Environmental Effects in Patients at High-Risk for Cancer
06/24/202019-1044/19-1044Anthony Olszanski A Phase 1a/1b Dose-escalation Study of Intravenously Administered SB 11285 Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors
11/11/201919-8014/19-8014Erin Tagai Decision Making for Medical Management of Low Risk Prostate Cancer: A Multilevel Qualitative Evaluation
07/13/202019-1043/19-1043Anthony Olszanski A Phase I Study of GNX102 in patients with Advanced Solid Tumors
07/31/202019-1054/19-1054Rishi Jain A Phase 1a/b Dose Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
06/29/202120-1005/20-1005Daniel Geynisman A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy
04/24/202020-1007/20-1007Anthony Olszanski A Phase I, Open Label, Multiple-Ascending Dose Study To Investigate The Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects with Metastatic or Locally Advanced Solid Tumors
02/03/202120-1009/20-1009Anthony Olszanski RT-90: A Phase I Dose Finding Study Of Low-dose Radiation With Sensitization Using 5-aminolevulinic Acid In Advanced Malignancies
08/27/202020-1021/20-1021Anthony Olszanski An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
11/03/202020-1025/20-1025Anthony Olszanski An Open-Label, Multicenter, Phase 1b/2 Study to Establish Safety, Tolerability, and Optimal Dosing Strategy of GLR2007 in Subjects with Advanced Solid Tumors
06/21/202120-8013/20-8013Camille Ragin AC3-IRONMAN: African Caribbean Cancer Consortium International Registry for Black Men with Advanced Prostate Cancer